Objectives: We developed a novel lipid formulation of nystatin suitable for parenteral administration, nystatin-intralipid (NYT-IL), with antifungal activity and reduced toxicity in mice. We investigated the pharmacokinetics, tissue distribution and immunomodulatory effect of NYT-IL in mice.
Methods: Nystatin levels in serum and organs were determined using HPLC after NYT-IL or nystatin administration in mice.